Matches in SemOpenAlex for { <https://semopenalex.org/work/W2045420218> ?p ?o ?g. }
- W2045420218 endingPage "351" @default.
- W2045420218 startingPage "351" @default.
- W2045420218 abstract "Profile of vintafolide (EC145) and its use in the treatment of platinum-resistant ovarian cancer Mathieu Luyckx,1,2 Raffaella Votino,1 Jean-Luc Squifflet,1,2 Jean-François Baurain2,31Gynecology and Andrology Unit, 2Centre du cancer, Gynecologic Oncology Group, 3Medical Oncology Unit, Cliniques Universitaires Saint-Luc, Brussels, BelgiumObjective: Our aim was to review the profile of vintafolide (EC145) and its rationale for use in platinum-resistant ovarian cancer. First we investigated the folate receptors (FRs), folate's pathway into cells, and its expression in normal and cancerous cells, before detailing the mechanism of action of vintafolide, its clinical applications, and the results of different study phases.Materials and methods: A literature search was conducted through Pubmed/Medline, Google, ClinicalTrials.gov and websites of pharmaceutical companies. Only articles in English were selected. All articles investigating folate receptor expression in ovarian cancer were selected first, than articles reviewing platinum resistance. Papers about vintafolide were collected, while those talking about synthesis and biochemistry concerns were excluded. The different Phase I and II studies were read, and an update on the website of pharmaceuticals companies were added.Results: FR is a bundle-membrane receptor that is expressed normally in some normal tissues on the apical surface of cells, but highly expressed in ovarian cancer cells (>80%). It collects folate through endocytosis. Chemotherapy does not modify its expression in ovarian cancer cells, and its expression appears to be mostly associated with a poor prognosis and platinum resistance. Vintafolide is a folate-desacetylvinblastine monohydrazide conjugate, allowing a liberation of the drug into the cytoplasm of cancerous cells via the FR-α (FR α) and endocytosis, with high specificity. Phase I studies showed a 2.5 mg bolus dose to be nontoxic, with moderately adverse events. Phase II clinical trials for the first time demonstrated a statistically significant improvement in disease-free survival in patients with platinum-resistant ovarian cancer, and in those with a very poor prognosis who had already received three to four lines of systemic chemotherapy. The greater benefits were observed in patients with highly expressed FR α.Conclusion: Vintafolide is a promising targeted agent for recurrent platinum-resistant ovarian cancer, first, thanks to its mechanism of action and the characteristics of FRa in ovarian cancer, and, second, because of the favorable results observed in the first clinical trials on platinum-resistant ovarian cancer. Phase III clinical trials are currently ongoing and are expected to confirm these results.Keyword: folate receptor, platinum-resistant ovarian cancer, chemotherapy" @default.
- W2045420218 created "2016-06-24" @default.
- W2045420218 creator A5013927992 @default.
- W2045420218 creator A5028034211 @default.
- W2045420218 creator A5052261998 @default.
- W2045420218 creator A5070139347 @default.
- W2045420218 date "2014-03-01" @default.
- W2045420218 modified "2023-10-17" @default.
- W2045420218 title "Profile of vintafolide (EC145) and its use in the treatment of platinum-resistant ovarian cancer" @default.
- W2045420218 cites W1795603515 @default.
- W2045420218 cites W1971341208 @default.
- W2045420218 cites W1974452295 @default.
- W2045420218 cites W1976290015 @default.
- W2045420218 cites W1977866186 @default.
- W2045420218 cites W1978478526 @default.
- W2045420218 cites W1979745458 @default.
- W2045420218 cites W2006122393 @default.
- W2045420218 cites W2010525082 @default.
- W2045420218 cites W2015217255 @default.
- W2045420218 cites W2016403748 @default.
- W2045420218 cites W2022724942 @default.
- W2045420218 cites W2023519068 @default.
- W2045420218 cites W2024132257 @default.
- W2045420218 cites W2025772696 @default.
- W2045420218 cites W2027689392 @default.
- W2045420218 cites W2042118791 @default.
- W2045420218 cites W2049490668 @default.
- W2045420218 cites W2051980540 @default.
- W2045420218 cites W2059027047 @default.
- W2045420218 cites W2060459188 @default.
- W2045420218 cites W2081522503 @default.
- W2045420218 cites W2084357980 @default.
- W2045420218 cites W2089777007 @default.
- W2045420218 cites W2093349285 @default.
- W2045420218 cites W2097265582 @default.
- W2045420218 cites W2101259585 @default.
- W2045420218 cites W2105678378 @default.
- W2045420218 cites W2106767659 @default.
- W2045420218 cites W2116725368 @default.
- W2045420218 cites W2117729836 @default.
- W2045420218 cites W2124979764 @default.
- W2045420218 cites W2127607483 @default.
- W2045420218 cites W2133374918 @default.
- W2045420218 cites W2137221411 @default.
- W2045420218 cites W2140853963 @default.
- W2045420218 cites W2146968962 @default.
- W2045420218 cites W2148111285 @default.
- W2045420218 cites W2151577023 @default.
- W2045420218 cites W2161069925 @default.
- W2045420218 cites W2162114522 @default.
- W2045420218 cites W2170192029 @default.
- W2045420218 cites W2313984291 @default.
- W2045420218 cites W2326721720 @default.
- W2045420218 cites W2328421677 @default.
- W2045420218 cites W2339809149 @default.
- W2045420218 cites W2052633507 @default.
- W2045420218 cites W3011900933 @default.
- W2045420218 doi "https://doi.org/10.2147/ijwh.s39696" @default.
- W2045420218 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3976235" @default.
- W2045420218 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24729732" @default.
- W2045420218 hasPublicationYear "2014" @default.
- W2045420218 type Work @default.
- W2045420218 sameAs 2045420218 @default.
- W2045420218 citedByCount "17" @default.
- W2045420218 countsByYear W20454202182014 @default.
- W2045420218 countsByYear W20454202182015 @default.
- W2045420218 countsByYear W20454202182017 @default.
- W2045420218 countsByYear W20454202182018 @default.
- W2045420218 countsByYear W20454202182019 @default.
- W2045420218 countsByYear W20454202182020 @default.
- W2045420218 countsByYear W20454202182021 @default.
- W2045420218 countsByYear W20454202182023 @default.
- W2045420218 crossrefType "journal-article" @default.
- W2045420218 hasAuthorship W2045420218A5013927992 @default.
- W2045420218 hasAuthorship W2045420218A5028034211 @default.
- W2045420218 hasAuthorship W2045420218A5052261998 @default.
- W2045420218 hasAuthorship W2045420218A5070139347 @default.
- W2045420218 hasBestOaLocation W20454202181 @default.
- W2045420218 hasConcept C121608353 @default.
- W2045420218 hasConcept C126322002 @default.
- W2045420218 hasConcept C143998085 @default.
- W2045420218 hasConcept C2776694085 @default.
- W2045420218 hasConcept C2780306303 @default.
- W2045420218 hasConcept C2780427987 @default.
- W2045420218 hasConcept C2780435969 @default.
- W2045420218 hasConcept C29456083 @default.
- W2045420218 hasConcept C502942594 @default.
- W2045420218 hasConcept C71924100 @default.
- W2045420218 hasConcept C96232424 @default.
- W2045420218 hasConceptScore W2045420218C121608353 @default.
- W2045420218 hasConceptScore W2045420218C126322002 @default.
- W2045420218 hasConceptScore W2045420218C143998085 @default.
- W2045420218 hasConceptScore W2045420218C2776694085 @default.
- W2045420218 hasConceptScore W2045420218C2780306303 @default.
- W2045420218 hasConceptScore W2045420218C2780427987 @default.
- W2045420218 hasConceptScore W2045420218C2780435969 @default.
- W2045420218 hasConceptScore W2045420218C29456083 @default.
- W2045420218 hasConceptScore W2045420218C502942594 @default.